

# REAL WORLD TESTING RESULTS REPORT TEMPLATE

## BACKGROUND & INSTRUCTIONS

Under the ONC Health IT Certification Program (Certification Program), health IT developers are required to conduct Real World Testing of their certified health IT (45 CFR 170.405). The Office of the National Coordinator for Health Information Technology (ONC) issues Real World Testing resources to clarify health IT developers' responsibilities for conducting Real World Testing, to identify topics and specific elements of Real World Testing that ONC considers a priority, and to assist health IT developers in developing their Real World Testing plans and results reports.

[A Real World Testing plan template](#) was created to assist health IT developers in organizing the required information that must be submitted for each element in their Real World Testing plan. To accompany the plan template, ONC has also provided this results report template.

While the use of this template is voluntary, health IT developers may find it useful in preparing their Real World Testing results report(s). Health IT developers must submit one year of results to address the Real World Testing of eligible products as outlined in their previous year's Real World Testing plan(s). If adjustments to approaches are made throughout Real World Testing, the health IT developer should reflect these adjustments in their Real World Testing results report. ONC expects that the results report will include a list of these changes, the reasons for them, and how intended outcomes were more efficiently met as a result.

**While every effort has been made to ensure the accuracy of restatements of 45 CFR Part 170, this template is not a legal document. The official program requirements are contained in the relevant laws and regulations. This resource should be read and understood in conjunction with the following companion resources, which describe in detail many of the Certification Program requirements referenced in this resource.**

- [Real World Testing–What It Means for Health IT Developers – Fact Sheet](#)
- [Real World Testing Resource Guide](#)
- [Real World Testing Certification Companion Guide](#)

Health IT developers should also review the following regulatory materials, which establish the core requirements and responsibilities for Real World Testing under the Certification Program.

- 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program final rule, [85 FR 25642](#) (May 1, 2020) (**ONC Cures Act Final Rule**)
  - [Section VII.B.5](#) — “Real World Testing”

## TEMPLATE INSTRUCTIONS

The following template is organized by elements required to be submitted in the Real World Testing results report. Each section provides a field for submitting responses and/or explanations for how the health IT developer addressed each required element in their Real World Testing approach. These fields serve as a foundation of information required for developing a Real World Testing results report and can be expanded with additional rows or columns to address the specific needs of the Real World Testing results being submitted.

## GENERAL INFORMATION

Plan Report ID Number: [For ONC-Authorized Certification Body use only]

Developer Name: PRN Software, LLC

Product Name(s): DoseSpot

Version Number(s): 8.0

Certified Health IT Product List (CHPL) Product Number(s): 15.04.04.3056.Dose.07.00.0.191106

Developer Real World Testing Plan Page URL:

<https://www.dosespot.com/real-world-testing>

Developer Real World Testing Results Report Page URL [if different from above]:

## [OPTIONAL] CHANGES TO ORIGINAL PLAN

*If a developer has made any changes to their approach for Real World Testing that differs from what was outlined in their plan, note these changes here.*

<b>Summary of Change</b> [Summarize each element that changed between the plan and actual execution of Real World Testing]	<b>Reason</b> [Describe the reason this change occurred]	<b>Impact</b> [Describe what impact this change had on the execution of your Real World Testing activities]

**[OPTIONAL] WITHDRAWN PRODUCTS**

*If a developer withdrew any products within the past year that were previously included in their Real World Testing plan, please provide the following information.*

<b>Product Name(s):</b>	
<b>Version Number(s):</b>	
<b>CHPL Product Number(s):</b>	
<b>Date(s) Withdrawn:</b>	
<b>Inclusion of Data in Results Report:</b> [Provide a statement as to whether any data was captured on the withdrawn products. If so, this data should be identified in the results report.]	

**SUMMARY OF TESTING METHODS AND KEY FINDINGS**

*Provide a summary of the Real World Testing methods deployed to demonstrate real-world interoperability, including any challenges or lessons learned from the chosen approach. Summarize how the results that will be shared in this report demonstrate real-world interoperability.*

*If any non-conformities were discovered and reported to the ONC-ACB during testing, outline these incidences and how they were addressed.*

*Note: A single Real World Testing results report may address multiple products and certification criteria for multiple care settings.*

We conducted Real World Testing in our production environment using database logs and reports to capture and demonstrate the success or failure of all ePrescribing scenarios.

## STANDARDS UPDATES (INCLUDING STANDARDS VERSION ADVANCEMENT PROCESS (SVAP) AND UNITED STATES CORE DATA FOR INTEROPERABILITY (USCDI))

*Both required and voluntary standards updates must be addressed in the Real World Testing plan. Real World Testing plans must include all certified health IT updated to newer versions of standards prior to August 31 of the year in which the updates were made.*

*Indicate as to whether optional standards, via SVAP and/or USCDI, are leveraged as part of the certification of your health IT product(s).*

Yes, I have products certified with voluntary SVAP or USCDI standards. (If yes, please complete the table below.

No, none of my products include these voluntary standards.

Standard (and version)	
Updated certification criteria and associated product	
CHPL Product Number	
Conformance measure	

### Care Setting(s)

*The expectation is that a developer's Real World Testing is conducted within each type of clinical setting in which their certified health IT is marketed. Health IT developers are not required to test their certified health IT in every setting in which it is marketed for use.*

*List each care setting that was tested.*

Pediatrics, Hospice, Dental, Behavioral Health, Medical

### Metrics and Outcomes

*Health IT developers should detail outcomes from their testing that successfully demonstrate that the certified health IT:*

1. is compliant with the certification criteria, including the required technical standards and vocabulary codes sets;
2. is exchanging electronic health information (EHI) in the care and practice settings for which it is marketed for use; and/or,
3. EHI is received by and used in the certified health IT.

(from 85 FR 25766)

Health IT developers could also detail outcomes that did not result from their measurement approach if that better describes their efforts.

Within this section, health IT developers should also describe how the specific data collected from their Real World Testing measures demonstrate their results. Where possible, context should be provided to the measures and results to understand the number of sites/users/transactions tested for the specified measures (i.e., the denominator for comparison to the reported results). If applicable, any Relied Upon Software that is used to meet a criterion's requirements should be included in this section.

Measurement /Metric	Associated Criterion(a)	Relied Upon Software (if applicable)	Outcomes	Challenges Encountered (if applicable)
EPrescribing New Prescription	§ 170.315(b)(3)(ii)(A)(1) ) Create new prescriptions (NewRx)		In the DoseSpot Prescribig App, Prescribers sent 39,498,821 New Rx prescriptions to pharmacies through Q1-Q4 2023.	
EPrescribing Cancel Prescription	§ 170.315(b)(3)(ii)(A)(3) ) Request and Response to Cancel prescriptions. (CancelRx, CancelRx Response)		In the DoseSpot Prescribing App, Prescribers and Agents requested 370,847 CancelRx from pharmacies through Q1-Q4 2023.  The DoseSpot Prescribing App received 325,139 inbound CancelRx Responses from pharmacies through Q1-Q4 2023	
EPrescribing Change Prescription	§ 170.315(b)(3)(ii)(A)(2) ) Request and Response to Change prescriptions. (RxChangeRequest, RxChange Response)		The DoseSpot Prescribing App received 226,074 inbound RxChange Requests from pharmacies through Q1-Q4 2023.  In the DoseSpot Prescribing App, Prescribers and Agents responded with 219,936 RxChange Responses through Q1-Q4 2023.	
EPrescribing Renewal Prescription Tests	§ 170.315(b)(3)(ii)(A)(4) ) Request and Response to Renew prescriptions. (RxRenewalRequest, RxRenewal Response)		DoseSpot received 1,323,513 RxRenewal Requests from pharmacies through Q1-Q4 2023.  In the DoseSpot Prescribing App, Prescribers and Agents sent 1,347,596 RxRenwal Responses through Q1-Q4 2023.	

**KEY MILESTONES**

*Include a list of key milestones that were met during the Real World Testing process. Include details on how and when the developer implemented measures and collected data. Key milestones should be relevant and directly related to outcomes discussed.*

*For each key milestone, describe when Real World Testing began in specific care settings and the date/timeframe during which data was collected.*

Key Milestone	Care Setting	Date/Timeframe
Real World Testing plans submitted	All	November 15, 2022
Data Entry, Test Preparations Database queries were written and calendar reminders were entered so testing and data collection could be completed on time and efficiently	All	December 2022
Data collection begun	All	January 2023
Data collection and review Reports for each measurement/metric were run quarterly and reviewed to ensure processes were working as expected	All	Quarterly 2023
End of 2023 Real World Testing/data collection Data was collected through December 31, 2023	All	December 31, 2023
Analysis and report creation Quarterly reports were combined to illustrate the data over the course of the year.	All	January 2024
Report Submitted	All	January 2024